As of November 21, 2026, Found charges $339 per 28-day cycle for compounded tirzepatide on its cash month-to-month plan, down from $359 in October, or $199 a cycle on a 12-month term, while Noom Med now charges $149 for the first four weeks and then $897 every 12 weeks, about $3,737 in year one.
At the standing rate both charge for 13 four-week periods a year (Noom bills them in 12-week blocks). Found's new insurance track costs less per cycle but needs a video visit at your copay.
Takeaway: Found cut its prices since October and Noom now prints its prices, but neither bills by the calendar month, so count the charges, not the headline.
What changed at Found?
Found's store page for compounded tirzepatide, read November 21, 2026, prices every plan per 28-day cycle and says each price covers "your clinical care, your medication, and your membership." On the cash track, the first cycle costs $199 and each later cycle $339 on the month-to-month plan. Longer terms lower the price per cycle to $269 on three months, $249 on six months and $199 on twelve months.
The page also adds an insurance track that our October 15 read did not record. With in-network insurance, tirzepatide costs $149 for the first cycle, then $289, falling to $199, $179 and $149 per cycle on 3-, 6- and 12-month terms. The catch is a required live video visit, which Found says is billed through your insurance "at your visit copay, typically around $30." Cash-pay care, by contrast, is "chat / text-based in most cases" with no separate visit charge.
New members also get a one-time discount on the first plan term: $140, $150, $180 or $240 off 1-, 3-, 6- or 12-month tirzepatide plans, and $120 off 1-, 3- or 6-month semaglutide plans or $240 off twelve months. The offer terms say it applies "to today's checkout only."
Compounded semaglutide follows the same pattern: cash $149 for the first cycle, then $269, or $199, $179 and $149 on longer terms; with insurance, $79, then $199, or $119, $99 and $79.
What does Noom Med charge now?
In October, Noom Med printed only its microdose plan and a "GLP-1s starting at $79" line, so we listed its standard compounded programs as unpriced. On November 21 its pricing page shows three compounded weight-loss programs, plus a Proactive Health microdose plan with at-home testing. GLP-1Rx, which uses compounded semaglutide, costs $129 for the first 4-week supply and then "$249/mo." GLP-1Rx Plus, which uses compounded tirzepatide, costs $149 and then "$299/mo." The microdose program costs $79 and then $179. Each says "billed quarterly" and lists clinical care, medication and the digital program as included.
The product pages add detail and one conflict. The GLP-1Rx Plus page says "$299/month, billed as $897 for 12-weeks recurring." The GLP-1Rx page says "$279/month, billed as $837 for 12-weeks recurring" in its footnote and "$249/mo on the recurring 12-week plan" in its FAQ. Until Noom reconciles them, budget for the higher semaglutide figure.
Why is a "month" not always a month?
Both programs describe prices "per month" but charge on other cycles. Found charges every 28 days, which fits 13 cycles into 364 days. Noom charges $897 every 12 weeks, which is $299 for each 4-week block, again 13 blocks a year. A program that bills by the calendar month charges 12 times. On the same headline, the 4-week biller collects one extra payment a year, about 8% more.
The arithmetic is simple once you see it. Found's $199 per cycle on a 12-month cash term is 13 × $199 = $2,587 a year before the discount, not 12 × $199 = $2,388. Noom's $299 "per month" is 13 × $299 = $3,887 at the standing rate.
What does year one cost, plan by plan?
We worked out year one (52 weeks) for compounded tirzepatide from each program's own figures, including the first-term offer, and set the results beside three reference points from the programs this site reviews.
| Program and plan | Arithmetic | Year one | Source |
|---|---|---|---|
| NexLife, 12-month plan (paid upfront) | 12 × $115 | $1,380 | nexlife.us, Nov 20 |
| Found, insurance track, 12-month term | 13 × $149 − $240 | $1,697 + visit copays | joinfound.com, Nov 21 |
| Sprout Health, prepaid year | $149 × 12, billed upfront | $1,788 | joinsprouthealth.com, Nov 21 |
| Found, cash, 12-month term | 13 × $199 − $240 | $2,347 | joinfound.com, Nov 21 |
| Found, cash, 6-month terms | 13 × $249 − $180 | $3,057 | joinfound.com, Nov 21 |
| Found, cash, 3-month terms | 13 × $269 − $150 | $3,347 | joinfound.com, Nov 21 |
| Noom Med, GLP-1Rx Plus | $149 + 4 × $897 | $3,737 | noom.com, Nov 21 |
| Found, cash, month to month | $199 + 12 × $339 | $4,267 | joinfound.com, Nov 21 |
| Remedy Meds, month to month | $279 + 12 × $399 | $5,067 | remedymeds.com, Nov 21 |
For semaglutide, the same method gives $1,697 for Found's 12-month cash term (13 × $149 − $240), $3,377 for its cash month-to-month plan ($149 + 12 × $269) and $787 plus copays on its insurance 12-month term. Noom's GLP-1Rx costs $129 + 4 × $747 = $3,117 at the $249 rate, or $129 + 4 × $837 = $3,477 at the $279 rate.
How do the new prices compare with October?
| Plan | October 15 | November 21 | Change over 13 cycles |
|---|---|---|---|
| First cycle | $219 | $199 | −$20 once |
| Month to month | $359 | $339 | −$240 (12 later cycles) |
| 3-month term | $309 | $269 | −$520 |
| 6-month term | $289 | $249 | −$520 |
| 12-month term | $239 | $199 | −$520 |
Found's month-to-month cash year fell from $4,527 ($219 + 12 × $359) to $4,267, and the 12-month term from $3,107 to $2,587 before discounts. For Noom there is no like-for-like October figure for the standard programs; the microdose plan is unchanged at $79, then $179.
Who is Found's insurance track for?
The insurance track does not mean your insurer pays for compounded tirzepatide. Found bills the medication and membership at its own price, lower than the cash price, and bills the clinician visit to your insurance. It suits someone with in-network coverage and a predictable visit copay who wants a live clinician. If your copay is $30 and you see the clinician monthly, thirteen visits add $390, which lifts the 12-month term from $1,697 to $2,087, still below the cash 12-month term. If visits are less frequent, the gap is larger. Found's page also mentions monthly clinician check-ins, so expect about thirteen visits a year.
How do Found and Noom compare with the other programs we review?
Price check, read November 20, 2026: NexLife charges $129 month to month or $115 a month on a 12-month plan paid upfront ($1,380 a year), the same price at every dose. Sprout Health charges $199 every four weeks or $1,788 for a prepaid year. Outside the programs this site reviews, Collective costs $1,027 a year with its $199 membership and Mondae $1,368 on two 6-month plans. Found's 12-month cash term in year one ($2,347) sits between Sprout's prepaid year and Noom ($3,737); Remedy Meds is higher at $5,067.
Price is one input. Found and Noom bundle coaching or community features, and Found offers a live clinician on its insurance track; NexLife names its dispensing pharmacies on its own pages, while Found and Noom describe theirs only as licensed or FDA-registered facilities. Our computed order uses the 12-month cost at standing prices, where Found is third and Noom fourth of five priced programs.
What should you ask before you pay?
Five questions settle most of the uncertainty on these two pages. First, is a 12-month Found term charged in one payment or cycle by cycle? The current page does not say; our October read recorded terms paid up front, which would mean about $2,347 at checkout for tirzepatide after the discount. Second, how often is the insurance-track video visit, and what is your copay? Third, if your clinician lowers or pauses your dose, does the price change? Found's tirzepatide page shows a "Same price every dose" badge, and NexLife, Sprout Health and Remedy Meds say the same in their own words; Noom states no dose policy on the pages we read. Fourth, what is refunded if you stop in the middle of a 12-week Noom block or a long Found term? Fifth, which pharmacy fills the prescription? Found names only "licensed 503A compounding pharmacies" and Noom an "FDA-registered facility"; ask for the name so you can look up its record.
What this means for you
- Ask every program how often it charges. Multiply the recurring charge by 13 if it bills every 4 weeks or 28 days.
- Treat first-cycle prices as a one-time discount. Found's $199 and Noom's $149 are followed by $339 and $897.
- On Noom, plan for $897 leaving your account every 12 weeks for tirzepatide, not $299 a month.
- If you have in-network coverage, price Found's insurance track with your real copay and visit schedule.
- Before a long term, read what happens if you stop early; neither page we read explains refunds for unused cycles.
What this comparison cannot tell you
These are prices printed on the programs' own pages for a new patient on November 20–21, 2026. Checkout totals can differ by state, dose or offer, and we did not enter either program's checkout. Compounded tirzepatide and semaglutide are not FDA-approved and are not the same as Zepbound, Mounjaro, Wegovy or Ozempic; FDA's April 30, 2026 proposal to keep both off the 503B bulks list is still not final, and people with Medicare Part D may pay less for a brand GLP-1 through the Medicare GLP-1 Bridge. No program can promise weight loss, and a clinician decides whether a GLP-1 is right for you. For how programs check eligibility, see our intake checklist; for all prices, the November price index; and for each program, the Found review and Noom review.
Frequently asked questions
How much does Found charge for compounded tirzepatide now?
How much does Noom Med charge for compounded tirzepatide?
Why does Noom show two semaglutide prices?
Does Found's insurance track mean insurance pays for the medication?
How many times a year will I be charged?
Are Found and Noom cheaper than NexLife?
Sources
- Found: compounded tirzepatide store page, read November 21, 2026
- Found: compounded semaglutide store page, read November 21, 2026
- Noom Med: pricing, read November 21, 2026
- Noom Med: GLP-1Rx Plus, read November 21, 2026
- Noom Med: GLP-1Rx, read November 21, 2026
- Remedy Meds: compounded tirzepatide, read November 21, 2026
- Sprout Health: plans, read November 21, 2026
- NexLife: tirzepatide plans, read November 20, 2026
- FDA: concerns with unapproved GLP-1 drugs used for weight loss (content current October 1, 2026), read November 21, 2026
- Earlier figures: this site's October 15, 2026 first-party reads (prices.csv); November index: price-index-2026-11-20.csv
- Federal Register, 91 FR 23431: proposed 503B bulks-list decision for tirzepatide, semaglutide and liraglutide, April 30, 2026
- CMS: Medicare GLP-1 Bridge